A substance becomes “controlled” when the federal government determines it has a potential for abuse and places it on one of five regulatory schedules. This designation, created by the Controlled Substances Act of 1970, restricts how the substance can be manufactured, prescribed, dispensed, and possessed. The core question behind every scheduling decision comes down to three things: how likely people are to abuse the substance, whether it has a legitimate medical use, and how easily it leads to dependence.
The Three Core Criteria
Every controlled substance is evaluated against three fundamental questions. First, does it have an accepted medical use in the United States? Second, what is its potential for abuse? Third, how likely is it to cause physical or psychological dependence? The answers to these three questions determine not only whether a substance is controlled, but which of the five schedules it lands in.
A substance doesn’t need to be illegal to be controlled. Many controlled substances are commonly prescribed medications. Oxycodone, Adderall, Xanax, and cough syrups containing codeine are all controlled. The designation simply means the government has decided the substance carries enough risk that its production, distribution, and use need to be tracked and restricted.
The Eight-Factor Test
Before a substance is scheduled, it goes through a formal evaluation based on eight factors written into federal law. These factors give the government a structured way to weigh the risks:
- Actual or relative potential for abuse: How likely are people to take this substance in ways it wasn’t intended to be used?
- Pharmacological effect: What does the substance actually do in the body, based on scientific evidence?
- Current scientific knowledge: How well-studied is the substance?
- History and current pattern of abuse: Is there a track record of people misusing it?
- Scope, duration, and significance of abuse: How widespread and serious is that misuse?
- Risk to public health: What broader harm could the substance cause at a population level?
- Dependence liability: How likely is the substance to cause physical or psychological dependence?
- Whether it’s a precursor: Can the substance be easily converted into something already controlled?
This eight-factor analysis was the framework used, for example, when the Department of Health and Human Services evaluated marijuana for potential rescheduling at President Biden’s request. Every scheduling or rescheduling decision runs through these same criteria.
How “Abuse Potential” Is Measured
Of the eight factors, abuse potential is the most important. It’s the threshold requirement: the Attorney General cannot place a substance on any schedule without first finding that it has a potential for abuse. But what does “abuse potential” actually mean in practice?
The FDA uses a combination of laboratory, animal, and human studies to answer that question. On the chemistry side, scientists look at whether a drug’s molecular structure can cross into the brain and whether it binds to the same brain receptors that known drugs of abuse target, such as the receptors involved in dopamine, opioid, or sedative pathways. In animal studies, researchers test whether animals will voluntarily self-administer the substance, whether they prefer environments where they received it, and whether stopping the drug abruptly causes withdrawal symptoms. If animals consistently choose to take a substance over a placebo, that’s a strong signal of abuse potential.
In human studies, volunteers with a history of recreational drug use rate how much they “like” the substance and whether it produces a “high” compared to a placebo. These subjective ratings, measured on standardized scales, are the most direct evidence of whether a drug is likely to be abused in the real world. Researchers also look at clinical trial data for side effects like euphoria, feeling drunk, hallucinations, or confusion, all of which flag abuse risk.
The Five Schedules
Once a substance passes the eight-factor analysis, it’s placed into one of five categories based on the severity of its risks.
Schedule I is the most restrictive. Substances here are considered to have a high potential for abuse, no currently accepted medical use in the United States, and a lack of accepted safety even under medical supervision. Heroin, LSD, and ecstasy are Schedule I. This classification makes a substance essentially unavailable for prescription, though researchers can obtain special permission to study it.
Schedule II substances also carry a high potential for abuse, but they have an accepted medical use. The key distinction is that using them can lead to severe psychological or physical dependence. Fentanyl, methamphetamine (which has a narrow medical use), oxycodone, and Adderall all fall here. These drugs require a new prescription each time; refills are not permitted.
Schedule III covers substances with a moderate to low potential for physical and psychological dependence. Testosterone, ketamine, and products containing less than 90 milligrams of codeine per dose are examples. Prescriptions can include refills.
Schedule IV substances have a low potential for abuse and a low risk of dependence. Xanax, Valium, and Ambien are typical examples. Schedule V is the least restrictive, covering preparations with limited quantities of certain narcotics, like some cough syrups with small amounts of codeine.
Who Makes the Decision
The scheduling process involves two branches of government working together. The Department of Health and Human Services, through the FDA, conducts the scientific and medical evaluation using the eight-factor test. Their assessment is sent to the Attorney General, who has the legal authority to actually add, remove, or reschedule a substance. In practice, the DEA handles this on the Attorney General’s behalf.
The process can be initiated in several ways. The DEA can start it on its own, the Department of Health and Human Services can request it, or a drug manufacturer or even a member of the public can petition for a substance to be scheduled or rescheduled. International treaty obligations, particularly those stemming from the Single Convention on Narcotic Drugs of 1961, can also trigger a scheduling review when the United Nations flags a substance for international control.
Analogues and Designer Drugs
One significant wrinkle in the law addresses substances that aren’t explicitly listed on any schedule but are chemically similar to ones that are. The Federal Analogue Act says that any substance “substantially similar” to a Schedule I or II drug, if it’s intended for human consumption, is automatically treated as a Schedule I controlled substance.
This provision exists largely to address designer drugs, where chemists tweak the molecular structure of a banned substance just enough to create something technically legal. To determine whether a substance qualifies as an analogue intended for human consumption, the law considers factors like how it’s marketed and labeled, whether the labeling matches any legitimate use, whether its price is consistent with what it claims to be, and whether there’s evidence of clandestine manufacturing or distribution. Notably, simply labeling a product “not for human consumption” is not enough on its own to escape the law.
State Scheduling Can Differ
Federal scheduling sets a nationwide floor, but individual states maintain their own controlled substance schedules and can be more restrictive. A substance that isn’t federally controlled might still be controlled in certain states, and penalties for the same substance can vary dramatically depending on where you are. Some states have also moved in the opposite direction from federal law on specific substances. Marijuana remains the most prominent example: it’s Schedule I under federal law, while dozens of states have legalized it for medical or recreational use. In those cases, state and federal law are in direct conflict, and which one applies depends on who is enforcing it.
The controlled substance designation is not permanent. Substances can be rescheduled to a less restrictive category, moved to a more restrictive one, or removed from the schedules entirely as scientific understanding, patterns of abuse, and medical applications evolve over time.